DelveInsight's DNA Synthesis Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Junk DNA” may hold the key to treating tough cancers. Existing drugs exploit weaknesses in cells with gene mutations. Researchers at King’s College London have identified a promising strategy for ...

David Baltimore explained to Mr Mandela, in a language so precise as only he could, that there was no vaccine for Aids and ...

HIV’s Tat protein blocks autophagy in macrophages, letting Mtb thrive. This may explain why HIV patients face higher TB risk even on ART.

The DNA synthesis inhibitors market is projected to witness substantial growth in the coming years, driven by the rising incidence of cancer diagnoses, growing awareness, the expanding pipeline ...

Researchers from King's have identified a new way to treat certain blood cancers using existing drugs, by turning a once-dismissed part of our DNA into a therapeutic target.

Investigate the advancements in detecting brain tumours through TERT expression, leading to more accurate grading and ...

Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications Promega ...

Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, ...

Many successful companies do stock splits to make their shares more affordable for retail investors. Hundreds of struggling companies are doing reverse stock splits to lift their flagging stocks above ...